

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Sugemalimab with chemotherapy for untreated  
metastatic non-small cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

|   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No.   |

|   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
| Not applicable.   |

|  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| Not applicable.  |

|  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
| Not applicable.  |

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 26 November 2021